


Elite™ Cell Cytotoxicity Assay Kit (Red Fluorescence)

CATALOG NUMBER: CA-C066, 100 assays

Description

The measurement of mitochondrial dehydrogenases (e.g. LDH) activity is a well-accepted assay to quantify cell numbers and monitor cell viability. Elite™ Fluorimetric Cell Cytotoxicity Assay Kit provides a fast, simple, accurate and homogeneous assay for the colorimetric or fluorimetric detection of viable cells. This assay is based on the observation that oxidized non-fluorescent blue resazurin is reduced to a red fluorescent dye (resorufin) by accepting an electron from mitochondrial respiratory chain in live cells. The amount of resorufin produced is directly proportional to the number of living cells.

Elite™ Fluorimetric Cell Cytotoxicity Assay Kit is more sensitive for cell proliferation and cytotoxicity than other assays such as MTT. The kit components are quite stable with minimal cytotoxicity, thus a longer incubation time (such as 24 to 48 hours) is possible if required. The characteristics of its high sensitivity (<100 CHO cells), non-radioactivity and no-wash method make the kit suitable for high throughput screening of cell proliferation or cytotoxicity against a variety of compounds. The assay can be performed in a convenient 96-well and 384-well microtiter-plate format with a filter set of Ex/Em = ~540/590 nm.



Features

- **Continuous:** Easily adapted to automation without mixing or separation
- **Convenient:** Formulated to have minimal hands-on time.
- **Wide Applications:** Cell proliferation and cytotoxicity.
- **Sensitive and Accurate:** As low as 100 cells can be accurately quantified.
- **Non-Radioactive:** No special requirements for waste disposal.

Kit Components

- **Component A:** Assay Solution 1 vial (20 ml)

Storage

Keep in freezer (-20 °C) and avoid exposure to light.

Materials Required (but not supplied)

- 96 or 384-well microplates: Tissue culture microplate with black wall and clear bottom is recommended.
- A fluorescence microplate reader: Capable of detecting emission at 590 nm with excitation at 530-560 nm.

Assay Protocol (for One 96-Well Plate)

1. Prepare cells and test compounds:

- 1.1 Plate 100 to 10,000 cells per well in a tissue culture microplate with black wall and clear bottom. Add test compounds into the cells, and incubate for a desired period (such as 24, 48 or 96 hours) in a 37 °C, 5% CO₂ incubator. For blank wells (medium without the cells), add the same amount of compound buffer. The suggested total volume is 100 µl for a well of a 96-well plate, and 50 µl for that of a 384-well plate.
- 1.2 Set up the following controls at the same time.
 - **Positive control** contains cells and known proliferation or cytotoxicity inducer.
 - **Negative control** contains cells but no test compounds.
 - **Vehicle control** contains cells and the vehicle used to deliver test compounds.
 - **Non-cell control** contains growth medium without cells.
Note: LDH in serum will contribute to background fluorescence.
 - **Test compound control** contains the vehicle used to deliver test compounds [Hank's balance salt solution (HBSS) or phosphate-buffered saline (PBS)] and test compound. Some test compounds have strong autofluorescence and may give false positive results.
Note: Match the total volume of all the controls to 100 µl for a well of a 96-well plate or 50 µl for that of a 384-well plate with growth medium.

2. Assay procedures:

- 2.1 Thaw and warm up the Assay Solution (**Component A**) to 37 °C, and mix it thoroughly before starting the experiments.
- 2.2 Add 20 µl/well (96-well plate) or 10 µl/well (384-well plate) of Assay Solution (Component A). Mix the reagents by shaking the plate gently for 30 seconds.
- 2.3 Incubate the cells in a 37 °C, 5% CO₂ incubator for 1 to 24 hours, protected from light.
Note 1: The appropriate incubation time depends on the metabolism rate of the individual cell type and cell concentration used. Optimize the incubation time for each experiment.
Note 2: Extremely prolonged incubation time is not recommended since resazurin could be converted to colorless dihydroresorufin.
- 2.4 Monitor the fluorescence intensity (bottom read) at Ex/Em = 540/590 nm. Alternatively, read the O.D. at 570 nm (the reference wavelength should be 600 nm) to determine the cell viability in each well.

3. Perform data analysis:

- 3.1. The background fluorescence reading from the non-cell control well is subtracted from the values for those wells containing the cells.
Note: The background fluorescence of the blank wells may vary depending on the sources of the growth media or the microtiter plates.
- 3.2. The fluorescence reading in each well indicates the cell number in that well.
- 3.3. Calculate the percentage of cell viability for samples and controls based on the following formula:
$$\% \text{ Cell viability} = 100 \times (F_{\text{sample}} - F_o) / (F_{\text{ctrl}} - F_o)$$

F_{sample} is the fluorescence reading in the presence of the test compound.
 F_{ctrl} is the fluorescence reading in the absence of the test compound (vehicle control).
 F_o is the averaged background (non-cell control) fluorescence intensity.



Data Analysis




Figure 1. CHO-K1 cell number response was measured with Elite™ Fluorimetric Cell Cytotoxicity Assay Kit. CHO-K1 cells at 0 to 10,000 cells/well/100 µl were seeded overnight in a Costar black wall/clear bottom 96-well plate. The cells were incubated with 20 µl/well of Assay Solution (Component A) for 3 hours at 37 oC. The fluorescence intensity was measured at Ex/Em = 540/590 nm with NOVOstar instrument (BMG Labtech). The fluorescence intensity was linear ($R^2 = 0.998$) to the cell number as indicated. The detection limit was 60 cells/well (n=6). The insert shows the enlargement of the lower end of the cell number response.

References

1. R. M. DeBAUN and G. de STEVENS, Arch.Biochem. 31, 300-308 (1951).
2. Nachlas, M.M. et al. Anal. Biochem. 1, 317-26 (1960).
3. D. W. De Jong and W. G. Woodlief, Biochim.Biophys.Acta 484, 249-259 (1977).
4. T. Mosmann, J.Immunol.Methods 65, 55-63 (1983).
5. C. Korzeniewski and D. M. Callewaert, J.Immunol.Methods 64, 313-320 (1983).
6. Decker, T. and Lohmann-Matthes, M.L. J. Immunol. Meth. 115, 61-9 (1988).
7. C. Legrand et al., J.Biotechnol. 25, 231-243 (1992).
8. G. Konjevic, V. Jurisic, I. Spuzic, J.Immunol.Methods 200, 199-201 (1997).
9. Singer, C.A. et al. J. Neurosci. 19, 2455-63 (1999).